The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Flying machine. Thanks for the links - always on lookout fir stuff that helps me make an informed decision.
I don't think Avacta have stated what their limit of detection is. They have suggested they achieve suitable binding in a lab test at nanamolar. They have sent Cytiva the affirmers to develop that result onto a LFD. We don't know if the technical elements of this have been achieved - that said we are all here because we believe it is likely.
I'm guessing (from some experience)
Testing of prototypes will involve known concentrations of covid. Then it will move to biogical samples from known covid patients - possibly comparing to PCR.
They then might do a batch field test.
I think the first RNS will be to say they have a prototype that works in lab.
Ben (x4)
Fair point, could also be Boris being confused!
*feel
Mikey I actually sorry for that lot. RNS tomorrow.. time to blow everyone out the water.
Flyingmachine, the importance of the sensitivity of the LFT to meet the testing needs has been discussed here at length. This is obviously well known by AS who has stated ‘performance is key’ in light of the requirements and competition. He also stated the key technical hurdle has been overcome. Why say that if the test doesn’t meet the sensitivity and specificity requirements? Avacta have also recently posted a blog highlighting the factors around improving LFT sensitivity. Coincidence?
You highlight the key issue being the consumer? That is why Avacta will launch a POC test first which is carried out by trained healthcare professionals. All the benefits of the LFT without the loss in sensitivity from user error.
It’s also very interesting to read how these sensitivity numbers are derived. They are based on trials in a lab using samples. Roche and Abbott came under fire recently in a peer review for their new antibody test quoting figures derived from lab samples (many potentially from the same people). Avactas first trials on the prototype will be done in the same way. This of course gives better results as the human factor And other variables are taken out of it.
What we really need is robust clinical trials across the target population in the relevant settings the test will be used in. Then we can compare apples with apples. There is reports the so called ‘gold standard’ PCR test has up to 30% error rate (false negative) due to sample collection errors. Does that mean the PCR tests are only 70% sensitive and not 98%+?
Sure the LFT test sensitivity is the key to huge success for Avacta in the short term and I appreciate all views however your short post did come across biased towards the general negative aspects of antigen sensitivity.
Yep.
Scenes over at the ODX BB however..
Ohh he had a few cracks appear is earlier regarding ODX.. few things he said me wonder.. if you back him.. I believe he is lol ??
TM he is, he's just constantly having a bubble..... even said Boris was pregnant earlier - or something similar
Why? Because I’m posting the truth rather than nonsense?
It’s not new news, it was announced ages ago, it’s an antibody test that hasn’t been developed yet. It’s completely irrelevant to Avacta.
The Elecsys Anti-SARS-CoV-2 serology test is processed in laboratories using Roche analysers that hospitals already have. Roche says its fully automated systems can provide results in approximately 18 minutes for one single test, with a capability to do 300 tests an hour, depending on the analyser
PL75 .. you are not invested here!!!
This is the lateral flow COVID-19 test from Roche that the PM is probably talking about. This link is from 2 weeks ago.
https://www.yahoo dot com/lifestyle/coronavirus-uk-government-in-talks-with-roche-about-highl
Why is this still being debated? The government rapid testing consortium are developing an antibody LFT. Bozza was not referring to Avacta.
But he will. Oh yes.
TBH could easily see Boris getting confused between the anti-body lateral flow tests and the anti-gen LTF and just saying 'pregnancy style test' off the cuff.
The Optigene antigen test in being trialled with the NHS so he's certainly well aware of that one.
Lots of Imperial scientists are on SAGE so also a likely contender.
I'm heavily in Avacta and so hope it is - but I'm (sadly) not overly convinced...
What about this article?
https://www.imperial.ac.uk/news/197236/rapid-coronavirus-test-receives-major-funding/
"The researchers aim to complete the development phase of the point-of-care diagnostic device, called QwikZyme, within the next six months."
It's good... but it's not quite Avacta
flyingmachine I (and others) have had dribble from *******s like you all the way from 56p, do you think your crap is going to sway people into selling? I am afraid 'boiler room' tactics won't really work here. If you want my shares, pm me and you can collect them from my house :)
Could it be Optigene?
I hope the A&E departments are ready for all the folk with varying swabs stuck up their noses.
Pleased Avacta are developing a more civilised saliva based test
Iceni interesting: https://www.genengnews.com/insights/iceni-diagnostics-hopes-for-home-use-coronavirus-test-this-autumn/
While the test is undergoing clinical assessment, Iceni Diagnostics is in parallel working to ensure that mass production can be rolled out once validation is completed. Product development manager Chris Liggett told GEN that the firm is “in discussions with two leading lateral flow device manufacturers who have the capacity and availability to support our launch plans for both the UK and overseas markets.”
Depends... the real game changer might turn up... not long now
Oh well I bet we'll be down another 1p tomorow, can't believe it!
It’s ODX and chums, they’re developing a home blood based antibody test as part of the rapid testing consortium. This is really old news.
https://www.thearmchairtrader.com/omega-diagnostics-shares-up-on-covid-19-rapid-test/
Or it could be the Qwikzyme test being developed quietly in the background by Imperial College London since April. They have EU funding....
https://eithealth.eu/covid-19-rapid-response/qwikzyme/
It mentions the difficulty of gaining high enough sensivity required in rapid antigen tests, especially when in the hands of non-skilled consumers. This challenge is described in this further article here....
https://www.sciencemag.org/news/2020/05/coronavirus-antigen-tests-quick-and-cheap-too-often-wrong?utm_campaign=ScienceNow&utm_source=JHubbard&utm_medium=Facebook
The key is sensitivity, if it isn't high enough (high 90's) it cannot be considered a great Covid test.
Agreed, also such a small company privately owned surely would have no capacity to supply the required amount
Unlikely as it mentions test ready in autumn.